Cantor Fitzgerald Starts Accelrys (ACCL) at Buy; Scientific R&D Enhanced with Software

Article Stock Quotes (1) Comments (0)

Cantor Fitzgerald initiates coverage on Accelrys (NASDAQ: ACCL) with a Buy. PT $10.00.

Analyst, Sung Ji Nam, said, "Since the merger with comparably-sized software provider Symyx in mid-2010, ACCL has focused on integration, restructuring, and strengthening its product portfolio over the last 18+ months. Although both ACCL and Symyx as standalone companies have struggled with top-line growth over several years, we believe the combined company has emerged better positioned to capitalize on high-growth opportunities within the scientific informatics market."

Nam expects Under-penetrated non-life sciences markets will also represent meaningful growth drivers...Strong balance sheet should help add tuck-in acquisitions of complementary assets.

For an analyst ratings summary and ratings history on Accelrys click here. For more ratings news on Accelrys click here.

Shares of Accelrys closed at $8.03 yesterday, with a 52 week range of $5.68-$8.45.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: UBS Starts Insmed (INSM) at Buy
• Goldman Sachs Starts Quintiles (Q) at Neutral
• Deutsche Bank Starts Quintiles (Q) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?